Treatment Monitoring of Patients Receiving CDK 4/6 Inhibitors for Hormone Receptor (HR) Positive, HER2 Negative Metastatic Breast Cancer (MBC) With or Without the Addition of DiviTum® Serum Thymidine Kinase 1 (TK1) Activity Testing
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Nusayba Bagegni, M.D.
Washington University School of Medicine
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Washington University School of Medicine
St Louis, Missouri, United States
Andrew Davis, M.D.Ashley Frith, M.D.Cynthia Ma, M.D., Ph.D.Foluso Ademuyiwa, M.D., MPHJingqin (Rosy) Luo, Ph.D.Katherine Clifton, M.D.Katherine Weilbaecher, M.D.Lindsay Peterson, M.D.Nusayba Bagegni, M.D.Rama Suresh, M.D.Ron Bose, M.D.Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 7 Mar 2022
- Primary completion
- 1 Aug 2028
- Completion
- 30 Sept 2030
- Last update posted
- 6 Jul 2026
- Registered enrollment
- 55
- Registry id
- NCT04968964
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.